The Jurkat cells are in fact used as a cellular system reporting the very first step of ADCC, i.e., the binding of a cognate antibody-tumor complex to an exogenous FcγRIIIa or CD16a, the induction of a signaling cascade from the immunoreceptor tyrosine-based activation motif (ITAM) (16) and the phosphorylation of NFAT2 and calcium flux (17), ultimately resulting in luminescence. The gene discussed is FCGR3A; the disease is neoplasm.